(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
This research study, called Summit, is looking at a new medicine called bezuclastinib for people with a rare blood condition known as systemic mastocytosis, specifically the 'indolent' or 'smoldering' types. These are forms of mastocytosis where symptoms haven't been severe enough to cause major organ damage but are still troublesome and not fully controlled by usual care. The study aims to see if bezuclastinib is safe and effective in reducing these symptoms. Participants will receive either bezuclastinib or a dummy pill (placebo) alongside their usual supportive care. The study also includes people whose symptoms are not well controlled by another medicine called avapritinib.
En un coup d'œil
De quoi parle cette étude ?
This study is investigating a new medicine called bezuclastinib for specific types of a rare blood disorder called systemic mastocytosis. This condition happens when too many special immune cells, called mast cells, build up in different parts of your body. The study is focusing on 'indolent' (ISM) and 'smoldering' (SSM) systemic mastocytosis, which are forms where symptoms can be disruptive but are not usually life-threatening like more advanced types. The main goal is to find out if bezuclastinib can safely and effectively reduce uncomfortable symptoms that haven't been properly managed with typical care.
To do this, some people in the study will receive bezuclastinib, while others will get a placebo (a dummy pill that looks like the real medicine but has no active ingredients). This is a common way to test new medicines, as it helps researchers understand if any improvements are truly due to the study medicine or something else. All participants will also continue to receive their usual supportive care for their symptoms. The study will look at how well the medicine works and also track any side effects.
This research is important because current treatments for mastocytosis often focus on managing symptoms rather than addressing the underlying cause. If successful, bezuclastinib could offer a new option for people whose symptoms are still troubling despite available care, potentially improving their quality of life. There's also a smaller part of the study looking at people who haven't found enough relief from another mastocytosis medicine called avapritinib.
Points clés
- This study is for people with specific types of systemic mastocytosis (ISM, SSM, BMM).
- It tests a new medicine called bezuclastinib against a dummy pill (placebo) to manage symptoms.
- The goal is to see if bezuclastinib is safe and effective in reducing symptoms not controlled by usual care.
- Participation involves taking pills and regular clinic visits for checks.
- You might get the active medicine or a placebo, and neither you nor your doctor will know which.
- You can stop participating at any time if you wish.
Qui peut être éligible ?
To be able to take part in this study, you must have been diagnosed with certain types of systemic mastocytosis: either 'indolent systemic mastocytosis' (ISM), 'smoldering systemic mastocytosis' (SSM), or 'bone marrow mastocytosis' (BMM). Your symptoms must be at a moderate to severe level, and despite trying at least two different symptom-reducing treatments for at least two weeks, your symptoms are still not well controlled. You also need to be generally well enough to participate, as assessed by your doctor.
However, there are reasons you might not be able to join. For example, if you have certain more aggressive types of mastocytosis, such as aggressive systemic mastocytosis or mast cell leukaemia, this study isn't for you. You also can't take part if you only have mastocytosis affecting your skin without it affecting your wider body. If you've recently had other treatments for mastocytosis, or have certain other medical conditions like significant bleeding problems, you also wouldn't be able to participate. Your doctor will carefully review all these criteria to determine if this study is suitable for you.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Have I been diagnosed with indolent, smoldering, or bone marrow mastocytosis?
- Are my mastocytosis symptoms moderate to severe and not well controlled by my current treatments?
- Suis-je généralement en assez bonne santé pour participer à une étude ?
- Have I had other mastocytosis treatments recently that might prevent me from joining?
- Do I need to take more than 10mg of prednisone (or similar steroid) per day?
En quoi consiste la participation ?
If you decide to take part in this study, you will be given either the new medicine, bezuclastinib, or a placebo (a dummy pill). You won't know which one you're receiving, nor will your study doctor, as this is a 'double-blind' study design. You'll take the tablets by mouth. The study is divided into several parts. You'll initially receive either bezuclastinib or placebo, and if you complete this part, you might have the option to continue into a later part of the study where everyone receives bezuclastinib.
Throughout your participation, you'll have regular visits to the clinic for assessments. These will include check-ups, blood tests, and discussions about how you're feeling and any symptoms you're experiencing. You'll also be asked about any side effects. The total length of time you'll be in the study will depend on which part of the study you join and how long you continue treatment, but it will involve multiple visits over several months.
Risques et avantages potentiels
Emplacements (57)
- Université de l'Alabama à BirminghamCode postal vérifiéBirmingham, États-Unis
- Mayo Clinic ArizonaCode postal vérifiéPhoenix, États-Unis
- One of a Kind Clinical Research CenterCode postal vérifiéScottsdale, États-Unis
- Modena Allergy and Asthma ClinicalCode postal vérifiéLa Jolla, United States
- Innovative Research of West FloridaCode postal vérifiéClearwater, États-Unis
- Mayo Clinic - JacksonvilleCode postal vérifiéJacksonville, États-Unis
- University of South FloridaCode postal vérifiéTampa, États-Unis
- Emory UniversityCode postal vérifiéAtlanta, États-Unis
- Rush UniversityCode postal vérifiéChicago, États-Unis
- Walter Reed National Military Medical CenterCode postal vérifiéBethesda, United States
- Allervie Clinical ResearchCode postal vérifiéGlenn Dale, United States
- Institute for Asthma and AllergyCode postal vérifiéWheaton, United States
Questions fréquentes
What is systemic mastocytosis?
It's a rare condition where special immune cells called mast cells build up in different parts of your body, which can cause various symptoms like skin rashes, stomach problems, or bone pain.
What does 'indolent' or 'smoldering' mean in mastocytosis?
These are types of systemic mastocytosis where the disease is not usually life-threatening, even though it can cause troublesome symptoms. They are less aggressive than other forms of the condition.
Qu'est-ce qu'un 'placebo' ?
A placebo is a dummy pill that looks exactly like the study medicine but contains no active ingredients. It's used in research to help scientists figure out if any changes are truly due to the new medicine.
Saurai-je si je reçois le vrai médicament ou le placebo ?
No, neither you nor your study doctor will know whether you are receiving bezuclastinib or the placebo. This is called a 'double-blind' study.
Can I stop participating in the study at any time?
Yes, you are free to leave the study at any point and for any reason, without it affecting your medical care.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.